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The majority of embolisms associated with atrial ﬁbrillation (AF) are from the left atrial appendage (LAA).
To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has
been no clinical information regarding the difference of the effects of congealing the ﬁbrinogenolysis
system among these oral anticoagulants. Here, we report a case of persistent AF, in whom apixaban,
factor Xa inhibitor resolved an LAA clot refractory to warfarin and direct thrombin inhibition. Factor Xa
inhibitor, apixaban, could resolve the left appendage thrombosis refractory to warfarin and dabigatran.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The majority of clot embolisms associated with atrial ﬁbrillation
(AF) are from the left atrial appendage (LAA). Before cardioversion
or catheter ablation, clot formation needs to be ruled out tradi-
tionally using transesophageal echocardiogram. To treat the existing
thrombus, warfarin, and novel anticoagulants have been used [1–
4]; however, there has been no clinical information regarding the
differences of the effects to congealing the ﬁbrinogenolysis system
among these oral anticoagulants. We report a case of persistent AF,
in whom apixaban, factor Xa inhibitor resolved LAA clot refractory
to warfarin and direct thrombin inhibition.2. Case report
A 63-year-old man with persistent AF was treated with warfarin
3.75 mg daily (prothrombin time-international normalized ratio [PT-
INR] range: 1.66–2.99). His medical history included thalamic
hemorrhage, hypertension, diabetes mellitus, and chronic kidney
disease (CKD) (stage 3). Anticoagulation with warfarin was initiated,
with a CHA2DS2-VASc score of two (hypertension and diabetes mel-
litus) and an HAS-BLED score of four (hypertension, CKD, history of
thalamic hemorrhage, and labile PT-INR). As the atrial ﬁbrillation was
quite symptomatic and refractory to the medication, catheter ablationblished by Elsevier B.V. This is an
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a).was planned. The time course of the anticoagulation therapy is shown
in Fig. 1. Initial transesophageal echocardiography (TEE) (Fig. 2A)
identiﬁed mobile LAA thrombus despite approximately one year of
therapeutic anticoagulation therapy with warfarin (PT-INR 1.66–2.99,
percent time in therapeutic PT-INR range (TTR) of 50%, D-dimer
0.47 μg/mL). Catheter ablation was deferred and more intensive
anticoagulation therapy targeting the INR range of 2.57–3.20, TTR
100% was continued for three months. Although the value of D-dimer
was o0.2 μg/mL, the second TEE showed no change in the thrombus
(Fig. 2B). Therefore, warfarin was switched to the direct thrombin
inhibitor, dabigatran 300 mg daily. Five months later, the third TEE
(Fig. 2C) showed the mobile LAA clot (D-dimer o0.20 μg/mL), and
anticoagulation was changed to apixaban 10 mg daily. Five months
later, the fourth TEE showed the resolution of the LAA thrombus
(Fig. 1D). The value of D-dimer remained o0.20 μg/mL. According to
his physical examination and neurological ﬁnding, there was no evi-
dence of cerebral and systemic embolism. Then, pulmonary vein
isolation was performed without any complication; since then, the
patient has been in sinus rhythm for over four months.3. Discussion
Non-vitamin K antagonist oral anticoagulants (NOACs) are
established as safe and effective ﬁrst-line medications for prophylaxis
of thromboembolism in patients with AF [5]. LAA thrombi are well
known as high-risk ﬁndings of thromboembolism. However, little
information regarding the effects of NOACs to LAA clot is available. To
the best of our knowledge, this case is the ﬁrst report to show the
efﬁcacy of apixaban to resolve an LAA clot, refractory to warfarin andopen access article under the CC BY-NC-ND license
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Fig. 1. Time course of anticoagulation therapy and transesophageal echocardiography (TEE).
Fig. 2. Panel A: transesophageal echo shows mobile thrombus in the left atrial appendage (LAA). Panel B: no change of LAA thrombus after three months of anticoagulation
with warfarin. Panel C: no change of LAA thrombus with dabigatran. Panel D: resolution of LAA thrombus after anticoagulation with apixaban.
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oagulant and useful for the resolution of LAA clots. Although there
has been little information on the differences of the coagulation-
ﬁbrinolysis balance among warfarin, direct thrombin inhibitor, and
factor Xa inhibitor, apixaban was reported to make thrombi mobile
or fragile by shifting the coagulation-ﬁbrinolysis balance to ﬁbrino-
lytic activity. Apixaban may have the optimal coagulation-ﬁbrinolysis
balance in patients with an existing thrombus. It has been suggested
that the factor Xa inhibitor does not change the existing thrombin
level, and will not completely suppress the thrombin production [6].
Thereby, a small amount of thrombin may be sufﬁcient to activate
high-afﬁnity platelet thrombin receptors to maintain hemostasis.
Factor Xa inhibitor inhibits the conversion of prothrombin to
thrombin; however, a direct thrombin inhibitor does not inhibit the
conversion [7]. In addition, factor Xa inhibitor strongly suppresses
thrombin generation at a lower concentration. Perzborn et al. [8]
reported a signiﬁcantly low level of ﬁbrinolytic activity at the low
concentration of dabigatran compared with rivaroxaban, possibly
due to the variable bioavailability of dabigatran. However, Ohyagi
et al. [9] reported the case of a patient who had an embolic stroke
during apixaban therapy for LAA thrombus. It is necessary to monitor
patients for thromboembolic complications after the initiation of
apixaban for the treatment of pre-existing LAA thrombus.4. Conclusion
Factor Xa inhibitor, apixaban, could resolve the left appendage
thrombosis refractory to warfarin and dabigatran. However, it is
necessary to monitor for thromboembolic complications following
the initiation of apixaban for a pre-existing LAA thrombus.Conﬂict of interest
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